- Home
- PRTA vs MYI Comparison
PRTA vs MYI Comparison
Compare PRTA & MYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRTA
- MYI
- Stock Information
- Founded
- PRTA 2012
- MYI 1992
- Country
- PRTA Ireland
- MYI United States
- Employees
- PRTA N/A
- MYI N/A
- Industry
- PRTA Biotechnology: Pharmaceutical Preparations
- MYI Investment Bankers/Brokers/Service
- Sector
- PRTA Health Care
- MYI Finance
- Exchange
- PRTA Nasdaq
- MYI Nasdaq
- Market Cap
- PRTA 809.8M
- MYI 697.2M
- IPO Year
- PRTA N/A
- MYI N/A
- Fundamental
- Price
- PRTA $6.58
- MYI $10.55
- Analyst Decision
- PRTA Buy
- MYI
- Analyst Count
- PRTA 9
- MYI 0
- Target Price
- PRTA $27.67
- MYI N/A
- AVG Volume (30 Days)
- PRTA 1.7M
- MYI 256.7K
- Earning Date
- PRTA 08-07-2025
- MYI 01-01-0001
- Dividend Yield
- PRTA N/A
- MYI 4.81%
- EPS Growth
- PRTA N/A
- MYI N/A
- EPS
- PRTA N/A
- MYI N/A
- Revenue
- PRTA $137,935,000.00
- MYI N/A
- Revenue This Year
- PRTA N/A
- MYI N/A
- Revenue Next Year
- PRTA $119.20
- MYI N/A
- P/E Ratio
- PRTA N/A
- MYI N/A
- Revenue Growth
- PRTA 54.55
- MYI N/A
- 52 Week Low
- PRTA $4.32
- MYI $9.32
- 52 Week High
- PRTA $25.42
- MYI $11.70
- Technical
- Relative Strength Index (RSI)
- PRTA 59.96
- MYI 60.90
- Support Level
- PRTA $5.96
- MYI $10.37
- Resistance Level
- PRTA $6.59
- MYI $10.65
- Average True Range (ATR)
- PRTA 0.38
- MYI 0.06
- MACD
- PRTA 0.15
- MYI 0.02
- Stochastic Oscillator
- PRTA 83.93
- MYI 89.66
About PRTA Prothena Corporation plc
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
About MYI Blackrock MuniYield Quality Fund III Inc
BLACKROCK MUNIYIELD QUALITY FUND III, INC. is a investment management company. Its investment objective is to provide shareholders with a high level of current income exempt from U.S. federal income taxes as is consistent with its investment policies and prudent investment management. The company invests in various sectors such as Transportation; Utilities; Health; Education; Tobacco and others.